A Multicenter, Open Label, Phase 1 Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INC280 Tablet Formulation With Food in Patients With cMET Dysregulated Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Capmatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 01 Mar 2018 Status changed from active, no longer recruiting to recruiting.
- 22 Feb 2018 Planned End Date changed from 18 Dec 2017 to 7 Jun 2018.
- 22 Feb 2018 Planned primary completion date changed from 6 Nov 2017 to 20 Apr 2018.